Overexpression of PD-L1 correlates with worse prognosis in many cancers, including prostate cancer, and in some cancers there is an increasing use of therapeutic interventions that, for example, block PD-1 with pembrolizumab or PD-L1 with atezolizumab in order to reduce immunosuppression in the tumor environment (36). Here, CD274 is linked to prostate carcinoma.